Research and Markets (http://www.researchandmarkets.com/research/zn2tm5/vimpat_epilepsy) has announced the addition of GlobalData's new report "Vimpat (Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
PharmaPoint Drug Evaluation Report - Vimpat (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
Vimpat (lacosamide) is an AED developed by UCB that is currently indicated as an adjunctive therapy for partial-onset seizures in individuals over the age of 17. The drug was approved in the EU and the US in 2008, and is available as tablets, syrup, and an injectable solution. Although the precise mechanism by which Vimpat exerts its antiepileptic effects in humans remains to be elucidated, in-vitro studies have indicated that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing (Errington et al., 2008). This
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Vimpat (lacosamide)
For more information visit http://www.researchandmarkets.com/research/zn2tm5/vimpat_epilepsy
- Sectors & Industries
- antiepileptic drugs